Niagen Bioscience Announces Selection Of Evotec As Contract Research Organization For IND-Enabling Studies Of NB4168 In Ataxia Telangiectasia
Share
Why It Matters
Niagen Bioscience hired Evotec, a research company, to help test a new medicine called NB4168 for a rare disease. This shows Niagen is moving forward with their medicine, which is a normal step when companies try to get permission from doctors to test drugs on people.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.